

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date

17 August 2023 (17.08.2023)



(10) International Publication Number

WO 2023/154519 A8

(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 417/14 (2006.01)
 C07C 301/00 (2006.01) C07D 471/04 (2006.01)
 C07D 207/34 (2006.01) C07D 487/04 (2006.01)
 C07D 213/56 (2006.01) C07D 487/10 (2006.01)
 C07D 213/61 (2006.01) C07D 491/048 (2006.01)
 C07D 231/14 (2006.01) C07D 491/08 (2006.01)
 C07D 233/32 (2006.01) C07D 491/107 (2006.01)
 C07D 233/90 (2006.01) C07D 495/04 (2006.01)
 C07D 235/26 (2006.01) C07F 7/08 (2006.01)
 C07D 307/68 (2006.01) A61K 31/4164 (2006.01)
 C07D 307/79 (2006.01) A61K 31/40 (2006.01)
 C07D 333/38 (2006.01) A61K 31/415 (2006.01)
 C07D 333/70 (2006.01) A61K 31/341 (2006.01)
 C07D 401/04 (2006.01) A61K 31/381 (2006.01)
 C07D 401/10 (2006.01) A61K 31/4436 (2006.01)
 C07D 401/12 (2006.01) A61K 31/506 (2006.01)
 C07D 401/14 (2006.01) A61K 31/5355 (2006.01)
 C07D 403/04 (2006.01) A61K 31/4439 (2006.01)
 C07D 403/14 (2006.01) A61K 31/444 (2006.01)
 C07D 405/04 (2006.01) A61K 31/496 (2006.01)
 C07D 405/14 (2006.01) A61K 31/4545 (2006.01)
 C07D 409/04 (2006.01) A61K 31/437 (2006.01)
 C07D 409/06 (2006.01) A61K 31/4985 (2006.01)
 C07D 409/12 (2006.01) A61K 31/4365 (2006.01)
 C07D 409/14 (2006.01) A61K 31/5025 (2006.01)
 C07D 413/12 (2006.01) A61K 31/66 (2006.01)
 C07D 413/14 (2006.01) A61K 31/695 (2006.01)
 C07D 417/04 (2006.01)

(21) International Application Number:

PCT/US2023/012929

(22) International Filing Date:

13 February 2023 (13.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/309,917 14 February 2022 (14.02.2022) US

(71) Applicant: ACCENT THERAPEUTICS, INC. [US/US];

1050 Waltham Street, Lexington, MA 02421 (US).

(72) Inventors; and

(71) Applicants: **WHITLOCK, Gavin**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **JENNINGS, Andrew J.**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US).


(72) Inventors: **DANIELS, Matthew H.**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **DUNCAN, Kenneth W.**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **SPARLING, Brian Andrew**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **LEE, Young-tae**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **CASTRO, Jennifer**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **RIBICH, Scott**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **SICKMIER, Ernest Allen**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **TASKER, Andrew Stewart**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US). **MILLS, James Edward John**; c/o Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US).

(74) Agent: **ZHANG, Xin** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF



(57) Abstract: Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

29 August 2024 (29.08.2024)

(15) Information about Correction:

see Notice of 29 August 2024 (29.08.2024)